Dante Labs to Offer Consumer Access to Whole Genome Sequencing for Disease and Health Information Using Illumina Sequencers
3.10.2019 10:00:00 EEST | Business Wire | Press release
Dante Labs today announced that it has begun installing Illumina next generation sequencing (NGS) technology at its new European headquarters in Italy to make whole genome sequencing (WGS) and whole exome sequencing (WES) available and accessible to individuals around the world through its global direct-to-consumer genomics platform. Sequencing will be carried out using Illumina’s most powerful sequencer, the NovaSeq™ 6000 System, providing high throughput genomic testing.
Andrea Riposati, Chief Executive Officer of Dante Labs, said: “We are delighted to work with Illumina’s leading platform technology to help more people around the world make informed decisions about their lifestyle and health based on the knowledge of their genome. We currently offer the only test that analyses 100% of people’s DNA. Through the stories of our users, we witness the transformative power of genomics every day, for individuals as well as for society as a whole. This is only the beginning.”
Paula Dowdy, Senior Vice President and General Manager, Commercial Operations, Europe, Middle East and Africa at Illumina, said: “We are pleased that Dante Labs has selected Illumina technology to provide WGS at a premium depth of coverage and rapid turnaround time. We share their vision of positively influencing personal healthcare by unlocking the power of the genome.”
Dante Labs’ WGS-based test kits are purchased online and the DNA sample is provided by spitting saliva into a small tube that is mailed back to the company. Proprietary bioinformatics analysis interprets the meaning of specific genetic variations and reports are delivered in an easy-to-understand, user-friendly format. Customers can gain knowledge of their predisposition to developing diseases such as hereditary cancers, heart failure, diabetes and other metabolic diseases, Alzheimer’s Disease, Parkinson’s Disease, autism and other common conditions. Testing can also inform people about their ability to metabolise certain medicines and can support the journey of individuals with rare and undiagnosed genetic diseases. More broadly, Dante Lab’s genomic analysis can help people make decisions about their diet, wellness and lifestyle.
Dante Labs selected Illumina sequencers for its growth based on Illumina’s role as a pioneer in advancing genomic technologies and applications combined with a reputation for accuracy, consistency and unsurpassed local technical support.
About Dante Labs
Dante Labs’ mission is to make the most advanced genomic tests accessible to everyone. To-date, it has customers in more than 80 countries who have personally experienced the power of the whole genome. Its global whole genome sequencing platform enables individuals to access actionable insights on their predispositions, reaction to medications and personalised medicine everywhere in the world. To learn more or to purchase a Dante Labs whole genome sequencing test, visit www.dantelabs.com and follow @DanteLabs.
Source: Dante Labs
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191003005322/en/
Contact information
Investors and Media:
Francesco Pennelli, Dante Labs
+39 389 596 1301
francesco@dantelabs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom